Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, Randomized, Phase III Trial of Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma (MRD2START)

Next Previous
Trial Profile

Multi-center, Randomized, Phase III Trial of Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma (MRD2START)

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tislelizumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms MRD2START

Most Recent Events

  • 02 Jun 2026 Planned End Date changed from 30 May 2034 to 28 Jun 2031.
  • 02 Jun 2026 Planned primary completion date changed from 28 Feb 2031 to 6 May 2026.
  • 03 Dec 2025 Planned initiation date changed from 30 Jun 2025 to 6 Jan 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top